Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp

Journal of the Royal Society of Medicine, Supplement

Volumn 96, Issue 43, 2003, Pages 66-72

  Jones, Andrew M ^a   Webb, A Kevin ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MARKER; MUCIN;

ACHROMOBACTER XYLOSOXIDANS; ADENOVIRUS; ANTIBIOTIC THERAPY; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; COMPLEX FORMATION; CONFERENCE PAPER; CROSS INFECTION; CYSTIC FIBROSIS; GENOTYPE; GRAM NEGATIVE INFECTION; HOSPITALIZATION; HUMAN; HYGIENE; INFECTION CONTROL; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LIFE EXPECTANCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MORBIDITY; NONHUMAN; PANDORAEA; PATIENT ATTITUDE; PATIENT EDUCATION; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; SEROPREVALENCE; SOCIAL ASPECT; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL TIME;

BETAPROTEOBACTERIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; CROSS INFECTION; CYSTIC FIBROSIS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 0038502461     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. CF Foundation. Patient Registry 1999: Annual Report, Bethesda: CF Foundation, 2000
2. Jones AM, Dodd ME, Webb AK. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001;17:295-301
3. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-74
4. Jones AM, Govan JR, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358:557-8
5. Govan JR, Brown PH, Maddison J, et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993;342:15-19
6. Coenye T, Liu L, Vandamme P, LiPuma JJ. Identification of pandoraea species by 16S ribosomal DNA-based PCR assays. J Clin Microbiol 2001;39:4452-5
7. Report M. MRSA in cystic fibrosis. London, 16 June 1997. J Hosp Infect 1998;40:179-91
8. Group CFTIC. A statement on Burkholderia cepacia. London: Cystic Fibrosis Trust, 1999
9. Group CFTCoI. Pseudomonas aeruginosa infection in people with cystic fibrosis. London: Cystic Fibrosis Trust, 2001
10. Govan JR, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992;48:912-30
11. Govan JR. Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex. J R Soc Med 2000;93:40-5
12. Weaver LT, Green MR, Nicholson K, et al. Prognosis in cystic fibrosis treated with continuous fludoxacillin from the neonatal period. Arch Dis Child 1994;70:84-9
13. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2000;2:CD001912
14. Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus. Lancet Infect Dis 2002;2:180-9
15. Report WP. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. J Hosp Infect 1998;39:253-90
16. Kreiswirth B, Kornblum J, Arbeit RD, et al. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science 1993;259:227-30
17. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000;38:1008-15
18. Boyce JM, Potter-Bynoe G, Chenevert C, King T. Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications. Infect Control Hosp Epidemiol 1997;18:622-7
19. Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001;84:160-2
20. Thomas SR, Gyi KM, Gaya H, Hodson ME. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect 1998;40:203-9
21. Farr BM, Salgado CD, Karchmer TB, Sheretz RJ. Can antibiotic-resistant nosocomial infections be controlled? Lancet Infect Dis 2001;i:38-45
22. Maiz L, Canton R, Mir N, Baquero F, Escobar H. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 1998;26:287-9
23. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990;336:1094-6
24. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33:1469-75
25. Ledson MJ, Gallagher MJ, Corkill JE, Hart CA, Walshaw MJ. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax 1998;53:432-6
26. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104:431-7
27. Mahenthiralingam E, Simpson DA, Speert DP. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Miorobiol 1997;35:808-16
28. LiPuma JJ, Spilker T, Gill LH, Campbell PW, 3rd, Liu L, Mahenthiralingam E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001;164:92-6
29. LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002;359:2002-3
30. Holmes A, Govan J, Goldstein R. Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health? Emerg Infect Dis 1998;4:221-7
31. Mahenthiralingam E, Coenye T, Chung JW, et al. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol 2000;38:910-13
32. Vandamme P, Holmes B, Vancanneyt M, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp nov. Int J Syst Bacteriol 1997;47:1188-200
33. Segonds C, Heulin T, Marty N, Chabanon G. Differentiation of burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gone and application to cystic fibrosis isolates. J Clin Microbiol 1999;37:2201-8
34. Agodi A, Mahenthiralingam E, Barchitta M, Giannino V, Sciacca A, Stefani S. Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status. J Clin Microbiol 2001;39:2891-6
35. Visca P, Cazzola G, Petrucca A, Braggion C. Travel-associated Burkholderia pseudomallei infection (Melioidosis) in a patient with cystic fibrosis: a case report. Clin Infect Dis 2001;32:E15-16
36. Schulin T, Steinmetz I. Chronic melioidosis in a patient with cystic fibrosis. J Clin Microbiol 2001;39:1676-7
37. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17:505-16
38. Grothues D, Koopmann U, von der Hardt H, Tummler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988;26:1973-7
39. Kelly NM, Fitzgerald MX, Tempany E, O'Boyle C, Falkiner FR, Keane CT. Does pseudomonas cross-infection occur between cystic-fibrosis patients? Lancet 1982;ii:688-90
40. Speert DP, Campbell ME. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect 1987;9:11-21
41. Speert DP, Lawton D, Damm S. Communicability of Pseudomonas aeruginosa in a cystic fibrosis summer camp. J Pediatr 1982;101:227-8
42. Smith DL, Smith EG, Gumery LB, Stableforth DE, Dalla Costa LM, Pitt TL. Epidemiology of Pseudomonas aeruginosa infection in cystic fibrosis and the use of strain genotyping. J Infect 1993;26:325-31
43. Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000;29:177-81
44. Hunfeld KP, Schmidt C, Krackhardt B, et al. Risk of Pseudomonas aeruginosa cross-colonisation in patients with cystic fibrosis within a holiday camp - a molecular-epidemiological study. Wien Klin Wochenschr 2000;112:329-33
45. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonized by P. aeruginosa. Lancet 2001;358:558-60
46. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166:983-7
47. Cheng K, Smyth RL, Govan JR, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639-42
48. Speert DP, Campbell ME, Henry DA, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 2002;166:988-93
49. Nelson JW, Tredgett MW, Sheehan JK, Thornton DJ, Notman D, Govan JR. Mucinophilic and chemotactic properties of Pseudomonas aeraginosa in relation to pulmonary colonization in cystic fibrosis. Infect Immun 1990;58:1489-95
50. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000;406:959-64
51. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288:1251-4
52. Jones AM, Dodd M, Doherty C, et al. Identification of airborne dissemination of epidemic multi-resistant strains of Pseudomonas aeruginosa at a CF centre during a cross-infection outbreak. Pediatr Pulmonol 2002;S24:295
53. Group CFTA. Antibiotic Treatment of Cystic Fibrosis. London: Cystic Fibrosis Trust, 2000
54. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5
55. Jones AM, Dodd ME, Doherty CJ, Govan JRW, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002;57:924-5
56. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998;316:1771-5
57. Zimakoff J, Hoiby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect 1983;4:31-40
58. Demko CA, Stern RC, Doershuk CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol 1998;25:304-8
59. Conway SP, Simmonds EJ, Littlewood JM. Acute severe deterioration in cystic fibrosis associated with influenza A virus infection. Thorax 1992;47:112-14
60. Ong EL, Mulvenna P, Webb KA. Varicella-zoster infection in adults with cystic fibrosis: role of acydovir. Scand J Infect Dis 1991;23:283-5
61. Webb AK. Two memorable patients. BMJ 2000;320:1324
62. Boyle MP, Farukhi Z, Nosky ML. Strategies for improving transition to adult cystic fibrosis care, based on patient and parent views. Pediatr Pulmonol 2001;32:428-36
63. Duff AJ. Psychological consequences of segregation resulting from chronic Burkholderia cepacia infection in adults with CF. Thorax 2002;57:756-8
64. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureas. Lancet 2001;357:1225-40